Literature DB >> 17977032

Ferroportin: lack of evidence for multimers.

Lisa M Schimanski1, Hal Drakesmith, Charlotte Talbott, Kerry Horne, John R James, Simon J Davis, Emma Sweetland, Judy Bastin, Diana Cowley, Alain R M Townsend.   

Abstract

Ferroportin is a multi-transmembrane glycoprotein that mediates iron export from cells. Mutations in ferroportin are linked to type IV hemochromatosis, a dominantly inherited disorder of iron metabolism. Multimers of ferroportin, whose existence may relate to the dominant inheritance pattern of disease, have been detected in some studies but not others. We looked for evidence of multimerization in several different types of experiment. We assayed the maturation of mutant and wild-type ferroportin and found that loss-of-function mutants had a reduced half-life but did not alter the stability of coexpressed wild-type. Using bioluminescence resonance energy transfer analysis, we tested how mature wild-type ferroportin behaved in intact live cell membranes. Ferroportin-ferroportin interactions gave the very low acceptor/donor ratio-independent energy transfer levels characteristic of random protein-protein interactions, consistent with ferroportin behaving as a monomer. Consistent with these experiments, we were unable to detect a dominant negative functional effect of mutant ferroportin on wild-type, even when expression of wild-type protein was titrated to low levels. These data suggest that dominantly inherited ferroportin disease does not result from the direct action of a mutated protein inhibiting a wild-type protein within multimers. We propose other possible mechanisms of disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977032     DOI: 10.1016/j.bcmd.2007.09.007

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  13 in total

1.  Multiple regulatory mechanisms act in concert to control ferroportin expression and heme iron recycling by macrophages.

Authors:  Carole Beaumont
Journal:  Haematologica       Date:  2010-08       Impact factor: 9.941

Review 2.  Parasite virulence, co-infections and cytokine balance in malaria.

Authors:  Raquel Müller Gonçalves; Nathália Ferreira Lima; Marcelo Urbano Ferreira
Journal:  Pathog Glob Health       Date:  2014-05-23       Impact factor: 2.894

Review 3.  Ceruloplasmin-ferroportin system of iron traffic in vertebrates.

Authors:  Giovanni Musci; Fabio Polticelli; Maria Carmela Bonaccorsi di Patti
Journal:  World J Biol Chem       Date:  2014-05-26

4.  Lipid raft-dependent endocytosis: a new route for hepcidin-mediated regulation of ferroportin in macrophages.

Authors:  Anne Auriac; Alexandra Willemetz; François Canonne-Hergaux
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

Review 5.  Hepcidin and ferroportin: the new players in iron metabolism.

Authors:  Ivana De Domenico; Diane McVey Ward; Jerry Kaplan
Journal:  Semin Liver Dis       Date:  2011-09-07       Impact factor: 6.115

6.  Ferroportin and erythroid cells: an update.

Authors:  Luciano Cianetti; Marco Gabbianelli; Nadia Maria Sposi
Journal:  Adv Hematol       Date:  2010-08-11

7.  Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter.

Authors:  Adrian E Rice; Michael J Mendez; Craig A Hokanson; Douglas C Rees; Pamela J Björkman
Journal:  J Mol Biol       Date:  2009-01-03       Impact factor: 5.469

Review 8.  Ironing out Ferroportin.

Authors:  Hal Drakesmith; Elizabeta Nemeth; Tomas Ganz
Journal:  Cell Metab       Date:  2015-10-01       Impact factor: 27.287

9.  Interleukin-10 regulates hepcidin in Plasmodium falciparum malaria.

Authors:  Honglei Huang; Abigail A Lamikanra; Matthew S Alkaitis; Marie L Thézénas; Abhinay Ramaprasad; Ehab Moussa; David J Roberts; Climent Casals-Pascual
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

Review 10.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.